Sun Pharma Q4 Net at 820 cr

Wednesday, 30 May 2012, 05:31 Hrs
cmt right
Comment Right
cmt right
cmt right
Printer Print Email Email
New Delhi: Sun Pharmaceutical Industries Ltd reported a consolidated net profit of Rs 820.21 crore for the fourth quarter ended March 31, 2012.

The company had posted a net profit of 442.75 crore for the same period of previous fiscal, Sun Pharma said in a filing to the BSE.

Net sales of the company stood at Rs 2,329.93 for the fourth quarter ended March 31, 2012 as against Rs 1,463.28 crore during the corresponding period of previous fiscal.

For the year ended March 31, 2012, the company posted a net profit of 2,587.25 crore compared to 1,816.06 crore in 2010-11.

"Taro Pharmaceutical Industries became a subsidiary of the company on September 20, 2010 therefore the figures for the current fiscal are not comparable with the corresponding figures for the previous financial year," the company said.

The company's board, which met today, recommended a dividend of 4.25 per equity share of Re.1 each for the financial year ended March 31, 2012.

In a separate filing the company said it has appointed Israel Makov as the Chairman of the company in place of Dilip Shanghvi, who has has stepped down from the position while continuing to remain as the company's Managing Director.

The company's board has also appointed Makov, a resident of Israel, as an additional director on the company's board, it said.

Shares of Sun Pharma today closed at 565.65 on the BSE, down 0.68% from its previous close.
Source: PTI
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..